MSCA Staff Exchanges involve organisations from the academic and non-academic sectors (including SMEs) from across the globe.
Support is provided for international, inter-sectoral and interdisciplinary mobility of R&I staff leading to knowledge transfer between participating organisations.
View this resource Bookmark this resourceFellowships will be provided to excellent researchers undertaking international mobility. Applications will be made jointly by the researcher and a beneficiary in the academic or non-academic sector.
Postdoctoral Fellowships either can take place in Europe (i.e. in an EU Member State or a Horizon Europe Associated Country) or in a Third Country not associated to Horizon Europe:
View this resource Bookmark this resourceMSCA Doctoral Networks will implement doctoral programmes, by partnerships of universities, research institutions and research infrastructures, businesses including SMEs, and other socio-economic actors from different countries across Europe and beyond. MSCA Doctoral Networks are indeed open to the participation of organisations from third countries, in view of fostering strategic international partnerships for the training and exchange of researchers.
These doctoral programmes will respond to well-identified needs in various R&I areas, expose the researchers to the academic and non-academic sectors, and offer training in research-related, as well as transferable skills and competences relevant for innovation and long-term employability (e.g. entrepreneurship, commercialisation of results, Intellectual Property Rights, communication). Proposals for doctoral networks can reflect existing or planned research partnerships among the participating organisations.
The selection procedure for doctoral candidates must be open, transparent and merit-based, in line with the Code of Conduct for the Recruitment of Researchers. The vacancy notice (to be widely advertised internationally, including on the EURAXESS website) must mention if the published rates include all employer and employee’s taxes and contributions. If possible, the gross salary (net salary + employee’s taxes and contributions) should be published.
MSCA Doctoral Networks are encouraged to lead to Industrial or Joint Doctorates.
View this resource Bookmark this resourceParticipants are invited to submit COST Action proposals contributing to the scientific, technological, economic, cultural or societal knowledge advancement and development of Europe. Multi- and interdisciplinary proposals are encouraged.
The Open Call Action proposal submission, evaluation, selection and approval (SESA) procedure is fully science and technology-driven and will ensure a simple, transparent and competitive proposal evaluation and selection process, reflecting the bottom-up, open and inclusive principles of COST.
Participants planning to submit a proposal for a COST Action will need to refer to the SESA guidelines and to the Open Call Announcement available on the Documents and Guidelines page.
View this resource Bookmark this resourceThe Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union
and industry associations representing the sectors involved in healthcare, namely COCIR (medical
imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe
(pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech
Europe (medical technology industry).
IHI JU aims to pioneer a new, more integrated approach to health research and builds on the experience
gained from the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU).
IHI JU aims to translate health research and innovation into real benefits for patients and society, and
ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health
research. Health research and care increasingly involve diverse sectors. By supporting projects that bring
these sectors together, IHI JU will pave the way for a more integrated approach to health care, covering
prevention, diagnosis, treatment, and disease management.
As current health challenges and threats are global, IHI JU should be open to participation by
international academic, industrial and regulatory actors, in order to benefit from wider access to data and
expertise, to respond to emerging health threats and to achieve the necessary societal impact, in
particular improved health outcomes for Union citizens
The Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union
and industry associations representing the sectors involved in healthcare, namely COCIR (medical
imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe
(pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech
Europe (medical technology industry).
IHI JU aims to pioneer a new, more integrated approach to health research and builds on the experience
gained from the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU).
IHI JU aims to translate health research and innovation into real benefits for patients and society, and
ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health
research. Health research and care increasingly involve diverse sectors. By supporting projects that bring
these sectors together, IHI JU will pave the way for a more integrated approach to health care, covering
prevention, diagnosis, treatment, and disease management.
As current health challenges and threats are global, IHI JU should be open to participation by
international academic, industrial and regulatory actors, in order to benefit from wider access to data and
expertise, to respond to emerging health threats and to achieve the necessary societal impact, in
particular improved health outcomes for Union citizens.
The Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union
and industry associations representing the sectors involved in healthcare, namely COCIR (medical
imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe
(pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech
Europe (medical technology industry).
IHI JU aims to pioneer a new, more integrated approach to health research and builds on the experience
gained from the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU).
IHI JU aims to translate health research and innovation into real benefits for patients and society, and
ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health
research. Health research and care increasingly involve diverse sectors. By supporting projects that bring
these sectors together, IHI JU will pave the way for a more integrated approach to health care, covering
prevention, diagnosis, treatment, and disease management.
As current health challenges and threats are global, IHI JU should be open to participation by
international academic, industrial and regulatory actors, in order to benefit from wider access to data and
expertise, to respond to emerging health threats and to achieve the necessary societal impact, in
particular improved health outcomes for Union citizens.
Published by ERA-NET NEURON
NeuronMaintenance, improvement, and restoration of human brain health are of fundamental importance and a worldwide priority. It has become increasingly evident that bidirectional communication between the central nervous system and the body has significant implications for maintaining both homeostatic and brain function. Abnormalities in brain–body interaction linked to genetic, environmental or lifestyle factors encompass a wide range of conditions affecting millions worldwide. Dysregulation of the brain-body axis can potentially contribute to or exacerbate various neurological and psychiatric disorders. The estimated prevalence can vary significantly depending on factors such as geographic location, population demographics, and advancements in medical diagnosis.
The study of bidirectional interactions between the central nervous system and the body is an emerging field of research that holds the potential to enhance our understanding of often overlooked pathophysiological processes involved in common neurological and psychiatric disorders. Expanding our current knowledge in this area is crucial as it serves as the initial step towards the development of therapeutic and preventive approaches aimed at preserving and improving brain health on a global scale.
The ‘Network of European Funding for Neuroscience Research’ (NEURON) has been established under the ERA-NET scheme of the European Commission (www.neuron-eranet.eu). The ERA-NET NEURON aims to coordinate and optimize research efforts and funding programmes of its partner countries/regions in the field of mental, neurological, and sensory disorders. Under the umbrella of NEURON, a joint transnational call (JTC 2024) in the field of bidirectional brain-body interactions is launched in 2024.
View this resource Bookmark this resourceSize of ERC Proof of Concept GrantsThe financial contribution will be awarded as a lump sum of EUR 150 000 for a period of 18 months. The ERC expects that normally proof of concept activities should be completed within 12 months. However, to allow for those projects that require more preparation time, the grant agreements will be signed for 18 months. Extensions of the duration of proof of concept projects may be granted only exceptionally.
The lump sum will cover the beneficiaries’ direct and indirect eligible costs for the project: if the project is implemented properly the amounts will be paid regardless of the costs actually incurred. The lump sum has been designed to cover the beneficiaries’ personnel costs, subcontracting, purchase costs, other cost categories and indirect costs.
View this resource Bookmark this resourceThe Chan Zuckerberg Initiative invites applications for five-year projects from patient-led rare disease advocacy organizations to join the Rare As One Network. Grantee organizations will accelerate research within individual disease areas and work across specified areas of scientific focus (channelopathies; ciliopathies; or inborn errors of metabolism) to develop shared research priorities and proposals.
View this resource Bookmark this resource
